L3VLUP
ProSign in

RARE · VRTX in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

RAREVRTX
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • RARE
  • VRTX
010203040202120222023202420252026
Holders and value by quarter
QuarterRAREVRTX
Q3 20206 holders, $1.6bn31 holders, $21.9bn
Q4 20208 holders, $3.0bn30 holders, $18.4bn
Q1 202110 holders, $2.6bn31 holders, $15.4bn
Q2 202114 holders, $2.3bn30 holders, $12.7bn
Q3 20219 holders, $2.0bn35 holders, $10.1bn
Q4 20218 holders, $1.6bn28 holders, $12.4bn
Q1 20228 holders, $1.5bn23 holders, $16.1bn
Q2 20228 holders, $1.1bn25 holders, $18.1bn
Q3 20226 holders, $487m22 holders, $18.4bn
Q4 20228 holders, $604m28 holders, $18.4bn
Q1 20239 holders, $502m26 holders, $21.4bn
Q2 202311 holders, $619m27 holders, $24.7bn
Q3 20238 holders, $397m33 holders, $24.3bn
Q4 20239 holders, $593m32 holders, $28.6bn
Q1 202412 holders, $513m31 holders, $29.8bn
Q2 202413 holders, $413m29 holders, $33.4bn
Q3 202416 holders, $809m27 holders, $33.5bn
Q4 202411 holders, $243m26 holders, $28.5bn
Q1 20258 holders, $158m21 holders, $35.4bn
Q2 20257 holders, $120m21 holders, $32.3bn
Q3 20258 holders, $94m22 holders, $25.9bn
Q4 20255 holders, $43m26 holders, $31.8bn
Q1 20265 holders, $48m25 holders, $31.8bn
Q2 20267 holders, $396m26 holders, $34.6bn
RARE

Ultragenyx Pharmaceutical In

Holders
11
Reported value
$243m
Buyers
7
Sellers
4

Breadth +3 among 94 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations
VRTX

Vertex Pharmaceuticals Inc

Holders
26
Reported value
$28.5bn
Buyers
14
Sellers
13

Breadth +1 among 94 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q4 2024

Among the 33 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only RARE (7)

Hudson Bay Capital Management LP, Moore Capital Management LP, Point72 Asset Management LP, Schonfeld Strategic Advisors LLC, Two Sigma Advisers LP, Two Sigma Investments LP, Verition Fund Management LLC

Only VRTX (22)

AllianceBernstein LP, AQR Capital Management LLC, ARK Investment Management LLC, Artisan Partners LP, Baillie Gifford & Co, Balyasny Asset Management LLC, Capital Research Global Investors, Capital World Investors, D. E. Shaw & Co., ExodusPoint Capital Management LP, Fidelity (FMR LLC), Invesco Ltd, Janus Henderson Group Ltd, Man Group PLC, MFS Investment Management, Millennium Management LLC, Neuberger Berman Group LLC, Renaissance Technologies LLC, T. Rowe Price Associates Inc, Voloridge Investment Management LLC, Wellington Management Group LLP, Winton Group Ltd

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →